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ABSTRACT 
Objective: Chronic Kidney Disease (CKD) is a silent epidemic of the 21st century. Cardiovascular disease (CVD) is a major cause of morbidity and 
mortality among patients with CKD. This study aims to evaluate the type of dyslipidemia in CKD patients and correlates with the severity of renal 
dysfunction in CKD patients. 
Methods: The observational study was conducted in the Department of General Medicine, PRM MCH, Baripada between May 2018 and January 
2019. 262 patients of CKD above 15 y of age, satisfying the inclusion and exclusion criteria were included in the study.  
Results: Out of 262 patients, 64.50% (169) were male and 35.50% (93) were females with M: F of 1.8:1. The age range was from 20 to 95. The 
average age of the patients in the study was 56.66+12.22 y. 45.04 % (118) of the patients were between 46 and 60 y of age. 68.70% of the patients 
had dyslipidemia. The comparison between lipid profiles of cases and controls showed a significant increase in total cholesterol, triglyceride, LDL 
and decrease in HDL. 
Conclusion: The prevalence of dyslipidemia in non-diabetic CKD is high. A high degree of abnormality is found in HDL with disease progression, 
which is statistically significant. Therefore, maintenance of desired lipid levels either through diet or early initiation of lipid-lowering drugs can be 
helpful in decreasing the risk of cardiovascular complications in CKD patients. 
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INTRODUCTION 
Chronic kidney disease (CKD) encompasses a spectrum of different 
pathophysiologic processes associated with abnormal kidney 
function and a progressive decline in glomerular filtration rate 
(GFR) [1]. CKD is a clinical syndrome due to irreversible kidney 
dysfunction leading to excretory, metabolic and synthetic failure 
culminating into the accumulation of non-protein nitrogenous 
substances and presenting with various clinical manifestations [2]. 
Chronic Kidney Disease (CKD) is a silent epidemic of the 21st 
century. Its occurrence is universal, not confined to the developed 
countries only. Globally, CKD is the 12th cause of death and the 17th 
cause of disability, respectively [3]. Estimated from population data, 
about 6% of the adult populations in the US have CKD stage 1 and 2, 
and 4.5% have CKD stage 3 and 4 [1].  
It has been estimated that the age-adjusted incidence rate of End-
Stage Renal Disease (ESRD) in India is around 229 per million 
population1, and more than one lakh new patients enter renal 
replacement programs annually in India [4]. It is estimated that the 
number of cases of kidney failure will increase disproportionately in 
developing countries, such as China and India, where the number of 
elderly people is increasing [5]. “Screening and Early Evaluation of 
Kidney Disease” (SEEK), a community-based voluntary health 
screening program started in India in 2006 with tests serum 
creatinine and urine analysis, reported a very high prevalence of 
17.4% of CKD using an abbreviated modified diet in renal disease 
(MDRD) formula, a glomerular filtration (GFR) estimation formula 
[3]. As per the database of CKD registry of India, the yearly incidence 
of ESRD in India is approximately 150–200 pmp and DM is an 
important cause of CKD in approximately 30–40% of the patients 
[6]. The prevalence of ESRD and patients on RRT has increased over 
the last two decades [7].  
It is well acknowledged that cardiovascular disease (CVD) is a major 
cause of morbidity and mortality among patients with CKD [1, 8]. 
Major outcomes of CKD include the progression of CKD to end-stage 
renal disease with increased risk for development of cardiovascular 
disease [9]. Most of the patients with CKD die from cardiovascular 
system complications before ever reaching Stage 5 CKD [1]. 
Even mild chronic renal dysfunction contributes actively to the 
development of CVD, so the American Heart Association has 
recommended that these patients should be classified in the highest 
risk group for developing cardiovascular events.  
Patients with CKD are subjected to accelerated atherosclerosis 
leading to increased cardiovascular complications. Patients with 
CKD have a reduction in the activity of lipoprotein lipase and hepatic 
triglyceride lipase. This interferes with the uptake of triglyceride-
rich, apolipoprotein B containing lipoproteins by the liver and in 
peripheral tissue, yielding increased circulation of these atherogenic 
lipoproteins [10]. Disturbances in lipoprotein metabolism are 
evident even in the early stages of CKD and usually follow a downhill 
course that parallels the deterioration in renal function [11]. Severe 
lipid metabolism disorders arise in patients with kidney failure and 
the lipid metabolism disorder peculiar to this patient group is 
known as uremic dyslipidemia [11], which may accelerate its 
progression [12]. Abnormal lipid profile in CKD includes 
hypertriglyceridemia, increase in triglyceride remnant Lp (a), 
increase in very-low-density lipoprotein (VLDL), decrease in high 
density lipoprotein (HDL), total cholesterol (TC) and low-density 
lipoprotein (LDL) usually within normal limits except in nephrotic 
syndrome patients [13]. Dyslipidemia is a major risk factor for 
coronary heart disease [14, 15]; it has prompted interest in the 
identification and management of abnormalities in plasma lipids and 
lipoproteins. 
Experimental studies suggest that hyperlipidemia accelerates renal 
damage due to progressive glomerulosclerosis and tubulointerstitial 
disease [16]. There is also growing evidence that abnormalities in 
lipid metabolism may contribute to renal disease progression [17]. 
Lipid-lowering treatment can reduce renal damage and preserve 
renal function [18]. The triglyceride-rich apoB containing 
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lipoproteins are found to be associated with accelerated 
deterioration of renal function [15]; however, the patho-
physiological mechanism is not fully understood. Use of lipid-
lowering agents may be helpful in correcting the lipid abnormalities, 
but a proper clinical trial is needed to establish the efficacy of 
hypolipidemic drugs on the attenuation of lipid abnormalities and to 
prevent the progression of renal disease [19]. 
We encounter a large number of patients with CKD with abnormal 
serum lipid profiles in our institution of Pandit Raghunath Murmu 
Medical College and Hospital, Baripada. As these being 
unpublished data we want to conduct a study, first of this type in 
our new college, to evaluate the type of dyslipidemia in CKD 
patients and correlates with the severity of renal dysfunction in 
CKD patients; which may have a future prognostic and 
management implication in patients with CKD. 
MATERIALS AND METHODS 
The observational study was conducted in the Department of 
General Medicine, PRM MCH, Baripada. The patients of CKD who had 
attended to department of general medicine OPD and who were 
admitted to department of general medicine, PRM MCH, Baripada 
between May 2018 and January 2019 were taken in our study. 
Inclusion criteria 
 All patients of CKD above 15 y of age satisfying the following 
criteria were included in the study. Criteria for diagnosis of CKD 
were as given by-National Kidney Foundation: K/DOQI clinical 
practice guidelines for Chronic Kidney Disease: Evaluation, 
Classification and Stratification [20]. 
CKD is defined as the presence, for at least 3 mo, of evidence of 
kidney damage with an abnormal GFR or alternatively, by a GFR<60 
ml/min/1.73m2 BSA [20]. 
Kidney damage is evidenced by- 
 Proteinuria>300 mg/day OR 
 Pathological abnormality found in histopathological study OR 
 Renal imaging study (USG) showing bilateral contracted 
kidneys<9 cm with thinned parenchyma and reduced 
corticomedullary differentiation.  
Exclusion criteria 
• Patients aged below 15 y of age 
• Patients on haemodialysis 
• Patients with diabetes mellitus, hypothyroid, liver disease, 
Coronary heart disease  
• Patients on lipid-lowering drugs 
• Kidney transplanted patients 
262 CKD patients were included in the study. All patients diagnosed 
with moderate to severe CKD, e-GFR was calculated according to the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 
equation, 2009 and divided into two groups. e-GFR was graded G1, 
G2, G3a, G3b, G4 and G5 as per the KDIGO 2012 guidelines [1]. 20 
healthy persons were taken as controls (Group A). Group B  
Patients with e-GFR>30 ml/min was considered as moderate CKD 
(Stage 3) (n=55)). Group C  Patients with e-GFR<30 ml/min was 
considered as severe CKD (Stage 4 and 5) (n=207)). 
Investigations  
All patients had undergone thorough clinical examination and 
laboratory investigations like complete blood counts, serum urea 
and creatinine, blood sugar and lipid profile. Ultrasound of the 
abdomen was done on every patient. A fasting serum lipid profile 
included serum cholesterol, triglyceride, HDL and LDL cholesterol 
on a Fully Automated analyzer (Erba EM360). 
Statistical analysis  
The statistical analysis was done using the Statistical Package for 
Social Sciences (SPSS) version 21.0. Univariate analysis was used in 
the description of demographic characteristics of the study 
population. Discrete variables were presented as frequency and 
percentages. Continuous variables were presented as means and 
standard deviation (SD) for unpaired data; the Student t-test was 
used to compare mean values (for two groups). Pearson’s 
correlation was used to determine the association between eGFR 
and other variables. Fisher’s exact test was used to determine the 
significant associations between categorical variables. P-value<0.05 
was considered statistically significant* and<0.001 was considered 
as statistically extremely significant**. 
Lipid classification was done according to NCEP-ATP III Guidelines:  
Risk factor  
Total cholesterol (mg/dl)  
<200 Desirable  
200-239 Borderline High 
>240 High  
Triglyceride (mg/dl)  
<150 Normal  
150-199 Borderline High 
200-499 High 
>500 Very High 
HDL-C (mg/dl)  
<40 Low 
>60 High 
LDL-C (mg/dl) Goal  
<100 Optimal  
100-129 Near or above optimal  
130-159 Borderline High  
160-189 High 
>190 Very high  
RESULTS 
During the study period, 262 patients with CKD attended to MOPD 
and admitted in the medicine ward of PRM MCH, Baripada, fulfill 
inclusion and exclusion criteria. All the cases were studied for the 
clinical presentation, risk factors and laboratory parameters. 
In our study, 262 patients with CKD were included; which 
constitutes 64.50% (169) of male and 35.50% (93) of females with 
M: F of 1.8:1; with age ranging from 20 to 95. The average age of the 
patients in the study was 56.66+12.22 y. The average age of the male 
and female patients in the study was 56.16+12.63 and 57.57+11.46 
y, respectively. 
Fig. 1 shows 45.04 % (118) of the patients were between 46 and 60 
y of age, followed by 27.86 % (73) of the patients were between 61 
and 75 y of age; the majority (66.41%) being below 60 y age group. 
79.01% (207 cases) of the patients in our study group belong to 
stage 4 and stage 5 chronic kidney diseases. All the cases in 15-30 y 
of age group are severe CKD (stage 4 and 5). 
In our study, we found that 32.82% CKD cases had hypertension. 
30.18% of male CKD cases had hypertension and 37.63% female 
CKD cases had hypertension. The association between HTN and 




Fig. 1: Age distribution of the CKD patients according to the stages of CKD as per e
  Male f%
CKD with HTN 51 30.18%
CKD without HTN 118 69.82%
Total 169 100%
The association between HTN and gender distribution is not statistically significant (p = 0.271).
 
The mean value of blood urea in study patients was 110.94
mg/dl, with range from 25 mg/dl to 421 mg/dl
serum creatinine was 4.16±2.62 mg/dl, with range from 1.5 mg/dl 
to 14.7 mg/dl. 18.70% of CKD patients had 
level>6 mg/dl. 
 
Table 2: Incidence of dyslipidemia among CKD patients with relation to the severity
  Group-B 
CKD with dyslipidemia 31 
CKD without dyslipidemia 24 
Total 55 
The prevalence of dyslipidemia among CKD patients with relation to the severity is statistically significant (p = 0.033*)
 
The mean value of serum cholesterol was 164.04±47.85 mg/dl
range from 44 mg/dl to 323 mg/dl. 19.61% of the cases were having 
hypercholesterolemia [fig. 2]. 
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Table 1: Gender distribution with or without HTN 
 female f% total 
 35 37.63% 86 
 58 62.37% 176 
  93 100%  262 
 
±62.47 
. The mean value of 
a serum creatinine 
68.70% (180) of the patients in the study population had 
dyslipidemia with any one of the parameters. 
patients had both abnormal triglyceride and HDL level
prevalence of dyslipidemia among CKD patients with relation to the 
severity is statistically significant
f% Group-C f% total 
56.36% 149 71.98% 180 
43.64% 58 28.02% 82 
 100% 207 100%  262 
Fig. 2: Total cholesterol levels in CKD 
 
, with The mean value of serum triglyceride 






f% p value  
32.82% p = 0.271 
67.18% 
100%  
Only 20 (7.63%) 
s. The 
 (p = 0.033*) (table 2). 
 
f% p value  





was 147.16±69.40 mg/dl, with 
37.40% of the cases were 
. 3]. 
 
The mean value of serum HDL was 51.50±16.72
from 4 mg/dl to 126 mg/dl. 21.37% of the study group was having 
HDL level below 40 mg/dl [fig. 4].  
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Fig. 3: Triglyceride levels in CKD 
 
 mg/dl, with range The mean value of serum LDL was 91.41±31.24 mg/dl
from 12 mg/dl to 203 mg/dl. 11.07% of the study group was having 
an increased level of LDL [fig. 5].
Fig. 4: HDL levels in chronic kidney disease 
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Table 3 shows the correlation coefficient of eGFR with lipid 
profile parameters. Negative Pearson’s correlation coefficient 
value indicates the level of triglyceride increase with the decline 
of GFR and positive Pearson’s correlation coefficient value 
indicates the level of cholesterol, HDL, LDL decrease with the 
decline of GFR. On correlating e-GFR with various parameters, 
statistical significance was observed with HDL (r= 0.1962, p= 
0.001**). 
 
Table 3: Correlation between e-GFR and lipid profile 
e-GFR vs. Pearson's correlation (r) Significance (p) 
Total cholesterol  0.112  0.070 
Serum triglyceride -0.0195  0.759 
HDL  0.1962  0.001** 
LDL  0.10988  0.076 
On correlating with e-GFR, statistical significance was observed with HDL (r= 0.1962, p= 0.001**). 
 
Table 4 shows the comparison between lipid profiles of cases and 
controls showed significant difference between total cholesterol (p= 
0.002*), triglyceride (p= 0.002*), HDL (p= 0.008*), LDL (p= 0.013*). 
On comparing various parameters between cases and controls, there 
is a significant rise in blood Urea (p<0.001) and serum Creatinine 
(p<0.001).
 
Table 4: Laboratory parameters of CKD patients and controls 
Parameters Controls (mean+SD) CKD patients (mean+SD) P-value 
n=20 n=262 
Blood urea (mg/dl) 28.50+12.63 110.94+62.47 <0.001** 
Serum creatinine (mg/dl) 1.03+0.17 4.16+2.62 <0.001** 
Total cholesterol (mg/dl) 130.25+23.32 164.04+47.85  0.002* 
Serum triglyceride (mg/dl) 99.45+28.28 147.16+69.40  0.002* 
HDL (mg/dl)  61.70+11.68 51.50+16.72  0.008* 
LDL (mg/dl) 76.70+16.24 94.41+31.24  0.013* 
Comparison between lipid profiles of cases and controls showed a statistically significant difference. Values are expressed as Mean + SD. 
 











P-value (A vs. B) 
control vs. 
moderate CKD 
P-value (A vs. C) 
control vs. 
severe CKD 
P-value (B vs. C) 
moderate CKD 
vs. severe CKD  
  n=20 n=55 n=207       
Age (years) 41.05+17.75 55.89+10.66 56.86+12.62 <0.001** <0.001** 0.602 
Systolic BP (mm Hg) 118.30+5.28 138.91+28.54 135.61+30.20 0.002* 0.001** 0.468 
Diastolic BP (mm Hg) 75.40+4.21 83.18+19.4 81.50+16.11 0.081 0.093 0.511 
Blood urea (mg/dl) 28.50+12.63 54.31+19.20 125.99+61.35 <0.001** <0.001** <0.001** 
Serum creatinine 
(mg/dl) 
1.03+0.17 1.91+0.25 4.76+2.64 <0.001** <0.001** <0.001** 
Total cholesterol 
(mg/dl) 
130.25+23.32 171.07+42.97 162.18+49.00 <0.001** 0.004* 0.221 
Serum triglyceride 
(mg/dl) 
99.45+28.28 142.8+62.14 148.32+71.30 0.004* 0.003* 0.601 
HDL (mg/dl)  61.70+11.68 58.53+15.75 49.63+16.50 0.415 0.002* <0.001** 
LDL (mg/dl) 76.70+16.24 101.37+29.93 92.56+31.39 <0.001** 0.027* 0.063 
Values are expressed as Mean+SD. Significant rise in total cholesterol, triglycerides, LDL and fall in HDL in group B and group C comparing to group 
A. There is an extremely significant fall in HDL when comparing group B and group C. 
 
Table 5 shows there is a significant rise in total cholesterol, 
triglycerides, LDL and fall in HDL in group B and group C comparing 
to control (group A) with decreasing e-GFR. There is an extremely 
significant fall in HDL (p<0.001**) when comparing group B and 
group C signifies increasing dyslipidemia with decreasing e-GFR, 
with increasing severity of CKD. 
DISCUSSION 
The current study was a cross-sectional study done to find out the 
derangement in lipid profile found in different stages of CKD, to find out 
its relationship with the severity of the disease in this part of the world. 
In our study group, 64.50% of patients were male and 35.50% of 
patients were female with M: F of 1.8:1. In CKD Registry of India 2007 
[21], the male cases were 68.9% and female cases were 31.1%. Similar 
results to the current study were seen in studies by Abraham et al. [22] 
and Ganta et al. [23]. Mean age of cases was 56.66±12.22 y and control 
was 41.05±17.75 y. This was similar to that of CKD Registry of India 
2007 [21] where the mean age of cases was 48.3±16.6 y and in the 
studies by Patel and Sirajwala et al. [24] and by Mohanty et al. [25]. 
As depicted in fig. 1, 46 and 60 y of age group consists the highest 
percentage of the study population with 45.04 % of the patients 
followed by 61 and 75 y of age group with 27.86 % of the patients. 
66.41% being below 60 y age group, which is a worrisome factor. It 
is bothering that all the cases in 15-30 y age group are severe CKD 
(stage 4 and 5). In CKD Registry of India 2007 [21], 71.2% of the 
cases belonged to age group of 19-60 y.  
The mean e-GFR was found to be 20.37±11.34 in cases; a significant 
fall in e-GFR in CKD cases. The mean eGFR of study by Sumanth and 
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Shobharani [26] was 22.22±8.70 showing results similar to our 
study. On basis of severity grades, 44.66% of cases were in G4 grade 
and 34.35% of cases were in G5 grade as shown in fig. 1. 79.01% of 
the study population was in G4 and G5 stage with e-GFR<30 ml/min. 
In CKD Registry India 2007 [21], 74.3% cases were in G4 and G5 
stage. In a study by Ganta et al. [23] 82.85% cases were in G4 and G5 
stage. These findings were similar to those in our study. 
32.82% CKD cases had hypertension in our present study. Combined 
diabetes mellitus and hypertension was found to be associated with 
43% of cases of CKD in Mahishale et al. study [27].  
30.18% male and 37.63% female CKD cases had hypertension. The 
association between HTN and gender distribution is not statistically 
significant (p = 0.271) [table 1]. 
68.70% (180) of the patients in our study population had 
dyslipidemia with any one of the parameters. The prevalence of 
dyslipidemia among CKD patients with relation to the severity is 
statistically significant (p = 0.033*) (table 2). The prevalence of 
dyslipidemia in non-diabetic CKD as calculated in Ganta et al. [23] is 
found to be 65.71% in patients with CKD without any prior history 
of diabetes. 
In our study, we had 19.61% of CKD cases with 
hypercholesterolemia. Ganta et al. [23], Saroj K et al. [28] and 
Anderson et al. [29] found 22.86%, 34.4%, 20% of CKD cases with 
hypercholesterolemia in their study respectively. In our study 
population, there is a marked elevation of triglycerides in 37.40% of 
patients. A study by Saroj K et al. reported a prevalence of 36.6% of 
hypertriglyceridemia in CKD [28]. 21.37% of the study group was 
having HDL level below 40 mg/dl. Similarly, Ganta et al. [23] study 
found a decreased level of HDL in 21.43% of cases with CKD. 11.07% 
of our study group population had an increased level of LDL. Poudel 
et al. reported an undesirable level of LDL in 38.03% of cases [30]. 
The LDL cholesterol is abnormal in only 12.86% of the study 
population in Ganta et al. [23] study, which is very similar to our 
study. 
As shown in table 3, negative Pearson’s correlation coefficient value 
indicates the level of triglyceride increase with the decline of GFR 
and positive Pearson’s correlation coefficient value indicates the 
level of HDL decrease with the decline of GFR; which was 
statistically significant (r= 0.1962, p= 0.001**). Paul and Kurien et al. 
[31] in separate studies showed a significant inverse correlation 
between triglyceride and e-GFR and significant positive correlation 
between high-density lipoprotein and e-GFR (p=<0.001). Kumari et 
al. [32] found a negative correlation between serum HDL-C level and 
serum creatinine levels, which were statistically significant. Muntner 
et al. have shown that people with low HDL values and high TG 
values have an increased risk of renal function alteration [33].  
Table 4 shows the comparison between lipid profiles of cases and 
controls showed significant difference between total cholesterol 
(p= 0.002*), triglyceride (p= 0.002*), HDL (p= 0.008*), LDL (p= 
0.013*). On comparing various parameters between cases and 
controls, there is a significant rise in blood Urea (p<0.001**) and 
serum Creatinine (p<0.001**). Mohanty et al. study also showed 
similar significant statistical association of total cholesterol (p= 
0.001), triglyceride (p= 0.001), HDL (p= 0.000), LDL (p= 0.000) 
between control and cases [25]. Kumari et al. study also found 
similar results to our study [32].  
Table 5 shows there is a significant rise in total cholesterol, 
triglycerides, LDL and fall in HDL in moderate CKD (group B) and 
severe CKD (group C) comparing to control (group A) with 
decreasing e-GFR. There is an extremely significant fall in HDL 
(p<0.001**); comparing moderate CKD (group B) to severe CKD 
(group C); signifies increasing dyslipidemia with decreasing e-GFR, 
with increasing severity of CKD. 
These findings indicate a rise in serum total cholesterol, 
triglycerides, low-density lipoproteins and a fall in high-density 
lipoproteins in CKD with a fall in e-GFR. Similar changes in lipid 
profiles were seen by Ganta V et al. [23], Patel and Sirajwala [24], 
Mohanty et al. [25] and Machnur et al. [34].  
LIMITATION  
A more widespread study including large number of patients and for 
longer duration; with appropriate clinical trial is required to attain a 
firm conclusion. Assessment of predialysis and post dialysis lipid 
profile parameters in the same CKD patient and follow up lipid 
profile evaluation after repeated hemodialysis will provide more 
consistent information on the effect of hemodialysis on lipid profile 
parameters in CKD patients.  
CONCLUSION 
The results of the present study provide valuable information and an 
association between lipid abnormalities and CKD patients, 
concluding that the prevalence of dyslipidemia in non-diabetic CKD 
is high enough to pose a major health problem and this problem of 
dyslipidemia increases with the severity of CKD. A high degree of 
abnormality is found in HDL with disease progression, which is 
statistically significant. This study confirms the presence of 
atherogenic lipid profile in CKD patients, which can lead to renal 
disease progression; and increased morbidity and mortality due to 
additional CVD risks. Therefore, maintenance of desired lipid 
parameters either through diet or early initiation of lipid-lowering 
drugs can be helpful in decreasing the risk of cardiovascular 
complications in CKD patients. 
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